Stockscreener 앱 받기
12.27
1.74%
0.21
전일 마감가:
$12.06
열려 있는:
$12.1
하루 거래량:
1.03M
Relative Volume:
0.57
시가총액:
$1.28B
수익:
$17.49M
순이익/손실:
$-78.50M
주가수익비율:
-10.22
EPS:
-1.2
순현금흐름:
$-52.85M
1주 성능:
-4.36%
1개월 성능:
-25.77%
6개월 성능:
-0.16%
1년 성능:
+2.59%
1일 변동 폭
$11.89
$12.30
1주일 범위
$11.85
$13.37
52주 변동 폭
$8.26
$19.41
Liquidia Corp Stock (LQDA) Company Profile
명칭
Liquidia Corp
전화
919.328.4400
주소
419 DAVIS DRIVE, SUITE 100, MORRISVILLE, NC
LQDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LQDA
Liquidia Corp
|
12.23 | 1.28B | 17.49M | -78.50M | -52.85M | -1.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Liquidia Corp Stock (LQDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-19 | 다운그레이드 | Oppenheimer | Perform → Underperform |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-08-16 | 개시 | Raymond James | Outperform |
| 2024-06-25 | 개시 | Oppenheimer | Perform |
| 2024-01-05 | 재확인 | Needham | Buy |
| 2022-09-19 | 재개 | Wedbush | Underperform |
| 2022-09-01 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2022-07-22 | 개시 | Ladenburg Thalmann | Buy |
| 2022-05-31 | 개시 | BTIG Research | Buy |
| 2022-05-26 | 개시 | BofA Securities | Buy |
| 2020-12-04 | 개시 | H.C. Wainwright | Buy |
| 2020-11-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-09-05 | 개시 | Wedbush | Outperform |
| 2018-08-20 | 개시 | Jefferies | Buy |
| 2018-08-20 | 개시 | Needham | Buy |
모두보기
Liquidia Corp 주식(LQDA)의 최신 뉴스
Wells Fargo Raises Price Target for Liquidia (LQDA) to $25 | LQD - GuruFocus
Liquidia (LQDA): B of A Securities Lowers Price Target to $23 | LQDA Stock News - GuruFocus
# Raymond James reiterates Strong Buy on Liquidia stock amid competition - Investing.com
Liquidia (LQDA) Sees Surge in Options Activity Ahead of Earnings - GuruFocus
# Raymond James reiterates Strong Buy on Liquidia stock amid competition By Investing.com - Investing.com UK
Biotech Hits A 'Home Run' And Slams Its Two Key Rivals - Investor's Business Daily
Liquidia (LQDA) Sees Surge in Options Activity Ahead of Earnings | LQDA Stock News - GuruFocus
Treprostinil Saga Continues - JD Supra
Liquidia at Jefferies Conference: Strategic Moves in PAH Market - Investing.com
BTIG Raises Liquidia Price Target Following YUTREPIA Approval - Insider Monkey
Judge Denies UTC Bid To Block Liquidia's Lung Drug - Law360
Liquidia (LQDA) Stock Price Target Raised by Analyst | LQDA Stoc - GuruFocus
Raymond James maintains strong buy on Liquidia stock following court ruling By Investing.com - Investing.com South Africa
BTIG raises Liquidia stock price target following FDA approval By Investing.com - Investing.com South Africa
Raymond James maintains strong buy on Liquidia stock following court ruling - Investing.com India
BTIG raises Liquidia stock price target following FDA approval - Investing.com
Liquidia Beats UTC Bid to Block Launch of Lung Drug Yutrepia - Bloomberg Law News
Liquidia stock rises following YUTREPIA shipment news By Investing.com - Investing.com Canada
Liquidia stock rises following YUTREPIA shipment news - Investing.com
Needham raises Liquidia Technologies stock price target after court ruling By Investing.com - Investing.com South Africa
Needham raises Liquidia Technologies stock price target after court ruling - Investing.com
Liquidia (LQDA) Gets Price Target Boost from Needham | LQDA Stock News - GuruFocus
Liquidia Set to Make First Commercial Shipment of Yutrepia for Pulmonary Hypertension - marketscreener.com
Liquidia starts commercial shipment of FDA-approved YUTREPIA By Investing.com - Investing.com India
Liquidia (LQDA) Begins Commercial Launch of YUTREPIA Following L - GuruFocus
Liquidia (LQDA) Begins Commercial Launch of YUTREPIA Following Legal Victory | LQDA Stock News - GuruFocus
Liquidia starts commercial shipment of FDA-approved YUTREPIA - Investing.com
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD - The Manila Times
BTIG reaffirms buy rating for Liquidia stock amid legal developments By Investing.com - Investing.com South Africa
Gold Is Bullish, But Be Aware Of Deeper Intraday Pullback; Elliott Wave Intraday Analysis - The Globe and Mail
BTIG reaffirms buy rating for Liquidia stock amid legal developments - Investing.com
Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - mx.advfn.com
Liquidia Told to Swap Two Defenses Ahead of Trial on UTC Patent - Bloomberg Law News
Liquidia (NASDAQ:LQDA) Given New $23.00 Price Target at Wells Fargo & Company - Defense World
Wells Fargo lifts Liquidia stock price target to $23 from $20 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Liquidia stock target to $35 on FDA nod By Investing.com - Investing.com South Africa
Liquidia (NASDAQ:LQDA) Given New $35.00 Price Target at HC Wainwright - Defense World
Scotiabank Raises Price Target for Liquidia (LQDA) to $37.00 | LQDA Stock News - GuruFocus
These Analysts Boost Their Forecasts On Liquidia - Benzinga
Scotiabank Increases Price Target for Liquidia (LQDA) After Yutrepia Approval | LQDA Stock News - GuruFocus
Liquidia (LQDA) Sees Target Price Increased by Wells Fargo Analy - GuruFocus
Liquidia (LQDA) Sees Target Price Increased by Wells Fargo Analyst | LQDA Stock News - GuruFocus
Liquidia Technologies stock target raised to $33 at Raymond James - Investing.com
Breaking Down Liquidia: 12 Analysts Share Their ViewsLiquidia (NASDAQ:LQDA) - Benzinga
Liquidia (LQDA) Price Target Raised to $35 by HC Wainwright | LQ - GuruFocus
H.C. Wainwright lifts Liquidia stock target to $35 on FDA nod - Investing.com
Liquidia (LQDA) Target Price Boosted Following FDA Approval | LQ - GuruFocus
Scotiabank raises Liquidia stock target to $37 on Yutrepia™ launch By Investing.com - Investing.com South Africa
Scotiabank raises Liquidia stock target to $37 on Yutrepia™ launch - Investing.com
Liquidia (LQDA) Target Price Boosted Following FDA Approval | LQDA Stock News - GuruFocus
Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference - Yahoo Finance
Liquidia Corp (LQDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Liquidia Corp 주식 (LQDA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Moomaw Scott | Chief Commercial Officer |
Jun 04 '25 |
Sale |
16.97 |
6,656 |
112,952 |
224,921 |
| Saggar Rajeev | Chief Medical Officer |
Jun 04 '25 |
Sale |
16.97 |
7,597 |
128,921 |
273,209 |
| JEFFS ROGER | Chief Executive Officer |
Jun 04 '25 |
Sale |
16.97 |
30,610 |
519,452 |
1,044,979 |
| Kaseta Michael | CFO and COO |
Jun 04 '25 |
Sale |
16.97 |
14,777 |
250,766 |
412,164 |
| Adair Jason | Chief Business Officer |
Jun 04 '25 |
Sale |
16.97 |
3,597 |
61,041 |
193,735 |
| Schundler Russell | General Counsel |
Jun 02 '25 |
Sale |
16.74 |
923 |
15,451 |
571,722 |
| Moomaw Scott | Chief Commercial Officer |
Jun 02 '25 |
Sale |
16.74 |
581 |
9,726 |
216,038 |
| Kaseta Michael | CFO and COO |
Jun 02 '25 |
Sale |
16.74 |
859 |
14,380 |
397,800 |
| Adair Jason | Chief Business Officer |
Jun 02 '25 |
Sale |
16.74 |
451 |
7,550 |
184,961 |
| Adair Jason | Chief Business Officer |
Apr 28 '25 |
Sale |
14.24 |
455 |
6,479 |
183,849 |
0.34%
7.69%
자본화:
|
볼륨(24시간):